Abstract 3906
Background
Anti-HER2 agents were a breakthrough in the treatment of HER2-enriched breast cancer (BC). In this study, we aimed to describe the real-life efficacy and safety of pertuzumab-trastuzumab-taxane (PTT) combination in BC patients.
Methods
This study was conducted by the Turkish Oncology Group and reached 35 centers nationwide. 309 visceral metastatic, and trastuzumab naive patients who received first line PTT were included.
Results
Patients' characteristics and treatment details are summarized in the table. Median progression-free survival (PFS) was 28.5 months (95% CI:15.6-41.4), while median overall survival (OS) was 40.3 months (95%CI: 26.9-53.7). Brain metastatic patients (n = 13, 4.2%) had worse PFS (16.8m vs. 28.5m; HR:3.9, 95% CI:1.7-9.2, p = 0.002) and OS (26.7m vs. 40.3m; HR:3.2, 95% CI:1.3-7.6, p = 0.009). Elderly patients (>65y) had significantly lower OS results (19.8m vs. 40.3m; HR:0.4, %95 CI:0.2-0.8, p = 0.01). Docetaxel was the choice in 268 patients (86.7%), while 41 patients (13.3%) received paclitaxel. There was no statistically significant difference in PFS (28.5 m vs. 24.1 m; p = 0.61) and OS (40.3 m vs. NR; p = 0.17) between taxane groups. Additionally, ≥10 cycles of docetaxel were not associated with improvement in outcomes compared with 6-10 cycles. One treatment-related death due to sepsis was noted. In 8 patients (2.6%), 5-40% ejection fraction decrease from baseline was detected without any sign of heart failure.Table: 325P
Demographic characteristics and treatment details
| N = 309 | % | |
|---|---|---|
| Median age (year, range) | 51 (22-82) | |
| >65 years-old patients | 39 | 12.6 |
| De-novo metastatic patients | 258 | 83.5 |
| Histopathology | ||
| IDC | 290 | 93.9 |
| ILC | 3 | 1 |
| Mixt | 5 | 1.6 |
| Others | 11 | 3.5 |
| Hormone receptor status | ||
| ER and/or PR positive | 170 | 55.2 |
| ER/PR negative | 138 | 44.8 |
| Unknown | 1 | 0.3 |
| Metastatic site distribution | ||
| Liver ± LN/skeletal | 112 | 36.3 |
| Lung ± LN/skeletal | 120 | 38.8 |
| Brain only | 6 | 1.9 |
| Brain + liver + lung | 7 | 2.3 |
| Liver + lung | 16 | 5.2 |
| Other | 48 | 15.5 |
| Only skeletal or only LN | - | - |
| Prior therapies | ||
| Prior anthracyclines | 51 | 16.5 |
| Prior trastuzumab | NA | NA |
| Treatment details | ||
| Median number of cycle (range) | ||
| Pertuzumab-trastuzumab | 10 (1-75) | |
| Docetaxel | 6 (1-23) | |
| Paclitaxel | 3 (1- 26) |
IDC: Invasive Ductal Carcinoma ILC: Invasive lobular carcinoma LN: Lymph Node
Conclusions
This real-life practice population differs from the CLEOPATRA study in terms of visceral only metastatic disease, and inclusion of brain metastatic patients. Regardless of these negative prognostic characteristics, results are concordant with the pivotal study. Elderly patients had overall lower PFS, which necessitates further investigation of pertuzumab-trastuzumab combination with cytotoxic/antihormonal therapies. To our knowledge, this is the largest scale real-life clinical practice study of PTT to date.
Clinical trial identification
Legal entity responsible for the study
Ece ESIN, on behalf of Turkish Oncology Group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract